Dermatology Times February 2026 Recap

🚨 Clearances, Approvals, Updates, and Recommendations

FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA

Galderma's relabotulinumtoxinA (Relfydess) aims to revolutionize wrinkle treatments with rapid results and lasting effects, pending FDA approval.

AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review

AbbVie seeks FDA and EMA approval for upadacitinib, a potential breakthrough systemic treatment for non-segmental vitiligo in adults and adolescents.

Narrow-Spectrum Sarecycline Approved for Moderate to Severe Acne in China

Almirall's sarecycline gains NMPA approval in China, offering a new oral treatment for moderate-to-severe acne, enhancing patient access and outcomes.

FDA Updates iPLEDGE REMS with New Modifications for Pregnancy Testing and Prescription Windows

FDA eases iPLEDGE REMS for isotretinoin acne care, allowing some at-home pregnancy tests and fewer lockouts to reduce administrative burden.

Photodynamic Therapy for sBCC Advances to FDA Review

The FDA has accepted Biofrontera’s supplemental new drug application seeking approval of Ameluz photodynamic therapy for superficial basal cell carcinoma (sBCC), with a decision expected by September 28, 2026.

ICYMI: Difamilast Ointment Expands Non-Steroidal Options in AD Care

In pivotal studies, significantly more patients achieved clear or almost clear skin after 4 weeks of twice-daily difamilast compared with vehicle.

CHE Experts Provide Framework for Diagnosis, Management, and Care in the United States

A new US consensus clarifies chronic hand eczema diagnosis and stepwise care, highlighting FDA-approved treatment and patient-reported outcomes.

🧬 Big Studies and Big Data

Phase 2 Data Highlight Roflumilast Cream in Infant AD

Arcutis reveals promising phase 2 results for roflumilast cream in infants with AD, highlighting safety and potential efficacy.

Sagimet and Ascletis Report Positive 52-Week Safety and Efficacy Data for Denifanstat in Acne

Sagimet and Ascletis shared denifanstat's 52-week safety results plus sustained improvements, highlighting a once-daily oral FASN inhibitor for acne.

JAAD Study Validates 487-GEP to Guide JAK Inhibitor Selection in Moderate to Severe AD

Castle Biosciences’ AdvanceAD-Tx test stratifies patients by molecular profile, identifying patients more likely to achieve faster and deeper responses with JAKs compared with Th2-targeted treatments.

Ixekizumab Plus Tirzepatide Outperforms Biologic Monotherapy

In the phase 3b TOGETHER-PsO trial, ixekizumab plus tirzepatide led to significantly higher rates of complete skin clearance and ≥10% weight loss.

UCB Presents 3-Year BE HEARD Trial Results for Bimekizumab in Moderate-to-Severe HS

UCB shares 3-year BIMZELX (bimekizumab) data in HS, showing sustained hidradenitis suppurativa lesion clearance and major severity reductions.

Brepocitinib Demonstrates Superior Efficacy in Phase 2 BEACON Trial for Cutaneous Sarcoidosis

Phase 2 BEACON study shows brepocitinib rapidly clears cutaneous sarcoidosis lesions with strong CSAMI gains and tolerability, as Priovant readies phase 3 program.

Rezpegaldesleukin Shows Deepening Response and Long-Term Durability in 52-Week AD Trial

REZOLVE-AD shows rezpegaldesleukin delivers durable atopic dermatitis control with monthly or quarterly dosing, supporting Nektar’s phase 3 plans.

Targeting MRGPRX2: Early Human Data for a Novel CSU Approach

Septerna to share phase 1 SEP-631 results at AAAAI, targeting MRGPRX2 to curb mast cell flares and broaden options for refractory CSU.

Meta-Analysis Supports 308 nm Excimer Laser for Plaque Psoriasis

Investigators reported consistent clinical improvement following twice-weekly excimer laser treatments.

Remibrutinib Meets Primary Endpoints in Phase 3 Trial for Chronic Inducible Urticaria Subtypes

Novartis reports RemIND phase 3 success and submits a supplemental New Drug Application to the FDA for symptomatic dermographism.

🗞 Market, Pharma, and Specialty News

Introducing Dermatology Times NP/PA Connect

Our new hub for dermatology NPs and PAs offers education, community, and resources to enhance patient care and professional growth.

Phase 1b/2 Trial Launches Evaluating Polyamine Pathway Inhibition in Metastatic Melanoma and Breast Cancer

Aminex Therapeutics has initiated a trial evaluating AMXT 1501 and DFMO, with implications for dermatologists managing advanced melanoma.

From Sidelines to Skin Care: The Dermatology Ads You May Have Missed From Super Bowl LX

Catch up on the health and dermatology-related commercials that aired during the 2026 Super Bowl.

Rare Disease Day Spotlight: Pipeline Updates in Epidermolysis Bullosa

Around 800 rare skin diseases affect 6.8 million people worldwide, including epidermolysis bullosa, generalized pustular psoriasis, ichthyosis, and erythropoietic protoporphyria.

Wealth, Workload, and Wellness: Key Findings From the PDPA 2025 Compensation Survey

PDPA’s 2025 survey, led by president Jamie Restivo, PA-C, reveals dermatology PA pay trends, productivity bonuses, benefits gaps, and satisfaction drivers shaping retention.

Alphyn Expands Pipeline with Phase 2 Trial of Zabalafin Hydrogel for Molluscum Contagiosum

Alphyn Biologics advances zabalafin hydrogel for MC, aiming for painless relief by clearing lesions and itch in pediatric patients.

⚖️ Strides for Skin Health Equity

Fractional CO₂ Resurfacing Improves Acne Scarring in Middle Eastern Patients

Fractional CO₂ laser treatment effectively reduces acne scars in Middle Eastern patients, balancing safety and efficacy for darker skin types.

World Cancer Day 2026: La Roche-Posay and ONS Partner to Launch Skin of Color Toxicity Repository

La Roche-Posay and the Oncology Nursing Society mark World Cancer Day with a first-of-its-kind tool, improving cancer care in patients with skin of color.

Rethinking Aging in Skin of Color: A Pigment-First Approach

Cheri Frey, MD, shares skin of color anti-aging strategies—pigment-first planning, safer lasers/peels, and techniques to prevent PIH.

New Phase 3 DISCREET Data Supports Long-Term Use of Apremilast for Genital Psoriasis

DISCREET phase 3 research shows oral apremilast eases genital psoriasis symptoms, improving itch, clearance, and sexual quality of life through 32 weeks.

Advancing Equity, Precision, and Awareness in Dermatology

This issue highlights clinical insights relevant to inflammatory conditions in diverse populations, emphasizing practical strategies for everyday practice.

Study Links Depression to Atopic Dermatitis–Related Immune Signature

Investigators identified overlap between the blood immune profiles of patients with depression and inflammatory skin diseases, highlighting the Th2 axis as a potential treatment target.

Breaking Barriers in Aesthetics: Joni Jefferson, DO on Representation, Patient Education, and the Power of Mentorship

Joni Jefferson, DO, spotlights skin of color dermatology, safer lasers, mentorship, and the future of aesthetic medicine during Black History Month.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.